Identification of a novel 974C→G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson Syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids

American Journal of Gastroenterology

Volumn 101, Issue 10, 2006, Pages 2427-2432

  Corpechot, Christophe ^a   Ping, Chen ^a,b   Wendum, Dominique ^a   Matsuda, Fumihiko ^b   Barbu, Véronique ^a   Poupon, Raoul ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b CENTRE NATIONAL DE GÉNOTYPAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILIRUBIN; ETHAMBUTOL; ISONIAZID; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; PYRAZINAMIDE; RIFAMPICIN; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE ACID BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; CASE REPORT; CELL MEMBRANE; CHOLESTASIS; DISEASE EXACERBATION; DOWN REGULATION; DRUG EFFICACY; DUBIN JOHNSON SYNDROME; GENE EXPRESSION; GENE IDENTIFICATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LIVER CELL; MALE; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBERCULOSIS;

ADULT; BILE ACIDS AND SALTS; BILIRUBIN; CHOLAGOGUES AND CHOLERETICS; CODON, NONSENSE; ENZYME INHIBITORS; HUMANS; JAUNDICE, CHRONIC IDIOPATHIC; MALE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RIFAMPIN; URSODEOXYCHOLIC ACID;

EID: 33749174572     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00695.x     Document Type: Article

References (41)

1. Kauffmann HM, Keppler D, Gant TW, et al. Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch Toxicol 1998;72:763-8.
2. Fromm MF, Kauffmann HM, Fritz P, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000;157:1575-80.
3. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005;129:476-85.
4. Beuers U, Bilzer M, Chittattu A, et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001;33:1206-16.
5. Fickert P, Zollner G, Fuchsbichler A, et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001;121:170-83.
6. Zollner G, Fickert P, Fuchsbichler A, et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 2003;39:480-8.
7. Poupon RE, Chretien Y, Poupon R, et al. Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy. Hepatology 1993;17:599-604.
8. Hoensch HP, Balzer K, Dylewizc P, et al. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 1985;28:475-7.
9. Bachs L, Pares A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102:2077-80.
10. Vavricka SR, Van Montfoort J, Ha HR, et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002;36:164-72.
11. Tirona RG, Leake BF, Wolkoff AW, et al. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003;304:223-8.
12. Payen L, Sparfel L, Courtois A, et al. The drug efflux pump MRP2: Regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol Toxicol 2002;18:221-33.
13. Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 2003;31:1296-9.
14. Payen L, Courtois A, Campion JP, et al. Characterization and inhibition by a wide range of xenobiotics of organic anion excretion by primary human hepatocytes. Biochem Pharmacol 2000;60:1967-75.
15. Konig J, Rost D, Cui Y, et al. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999;29:1156-63.
16. Ohkubo H, Okuda K, Iida S, et al. Ursodeoxycholic acid oral tolerance test in patients with constitutional hyperbilirubinemias and effect of phenobarbital. Gastroenterology 1981;81:126-35.
17. Kawasaki H, Yamanishi Y, Kishimoto Y, et al. Abnormality of oral ursodeoxycholic acid tolerance test in the Dubin-Johnson syndrome. Clin Chim Acta 1981;112:13-9.
18. Gerk PM, Vore M. Tauroursodeoxycholate and taurocholate are transported by human MRP2 in the presence of certain MRP2 substrates. Hepatology 2004;40:488A (AASLD abstract).
19. Stieger B, Fattinger K, Madon J, et al. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000;118:422-30.
20. Byrne JA, Strautnieks SS, Mieli-Vergani G, et al. The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002;123:1649-58.
21. Hirohashi T, Suzuki H, Takikawa H, et al. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 2000;275:2905-10.
22. Rius M, Nies AT, Hummel-Eisenbeiss J, et al. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003;38:374-84.
23. Zollner G, Halilbasic E, Wagner M, et al. Cholic acid (CA) and ursodeoxycholic acid (UDCA) exert different effects on hepatic and renal expression of Mrp4 and Mrp6, two novel ABC transporters. AASLD New Orleans May 2004:A16 (abstract).
24. Trauner M, Arrese M, Soroka CJ, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997;113:255-64.
25. Kullak-Ublick GA, Baretton GB, Oswald M, et al. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol Res 2002;23:78-82.
26. Kojima H, Nies AT, Konig J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 2003;39:693-702.
27. Shoda J, Suzuki H, Sugiyama Y, et al. Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol Res 2003;27:323-6.
28. Mor-Cohen R, Zivelin A, Rosenberg N, et al. A novel ancestral splicing mutation in the multidrug resistance protein 2 gene causes Dubin-Johnson syndrome in Ashkenazi Jewish patients. Hepatol Res 2005;31:104-11.
29. Machida I, Wakusawa S, Sanae F, et al. Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan. J Gastroenterol 2005;40:366-70.
30. Cebecauerova D, Jirasek T, Budisova L, et al. Dual hereditary jaundice: Simultaneous occurrence of mutations causing Gilbert's and Dubin-Johnson syndrome. Gastroenterology 2005;129:315-20.
31. Hulot JS, Villard E, Maguy A, et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005;15:277-85.
32. Wada M, Toh S, Taniguchi K, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998;7:203-7.
33. Tate G, Li M, Suzuki T, et al. A new mutation of the ATP-binding cassette, sub-family C, member 2 (ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Genes Genet Syst 2002;77:117-21.
34. Kajihara S, Hisatomi A, Mizuta T, et al. A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. Biochem Biophys Res Commun 1998;253:454-7.
35. Wakusawa S, Machida I, Suzuki S, et al. Identification of a novel 2026G→C mutation of the MRP2 gene in a Japanese patient with Dubin-Johnson syndrome. J Hum Genet 2003;48:425-9.
36. Machida I, Inagaki Y, Suzuki S, et al. Mutation analysis of the multidrug resistance protein 2 (MRP2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol Res 2004;30:86-90.
37. Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999;64:739-46.
38. Materna V, Lage H. Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient. J Hum Genet 2003;48:484-6.
39. Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997;25:1539-42.
40. Tsujii H, Konig J, Rost D, et al. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999;117:653-60.
41. Mor-Cohen R, Zivelin A, Rosenberg N, et al. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001;276:36923-30.